

PET/CT Imaging Request Form

NUCLEAR MEDICINE & PET
LIVERPOOL HOSPITAL

SYDNEY SOUTH WEST
AREA HEALTH SERVICE
NSW HEALTH

DR JOHN CHU AND ASSOCIATES
112006W

1 ELIZABETH ST, LIVERPOOL NSW 2170
PHONE: 9828-3502, FAX: 9828-3529

Patient Identification

Name: _____ DOB: ____/____/____ MRN: _____
Address: _____
Phone:(H): _____(W): _____(M): _____
Weight (kg): _____ NIDDM/IDDM: _____ Inpatient: Outpatient

Urgent (<7 days) Reason: _____ 7-14 days By ____/____/____

Clinical Indication

Primary Site of Disease: _____
Histology/Pathology: _____ Pre PET stage: T N M

Surgery Type: _____ Most recent: ____/____/____
Radiotherapy Region: _____ Last: ____/____/____ Next: ____/____/____
Chemotherapy: _____ Last: ____/____/____ Next: ____/____/____

Indications for PET (Tick Only One)

- | | |
|---|--|
| <input type="checkbox"/> Characterisation of SOLITARY PULMONARY NODULES
Where the lesion is considered unsuitable for transthoracic fine needle aspiration biopsy, or for which an attempt at pathological characterisation has failed (61523/61526). | <input type="checkbox"/> Staging of proven GASTRIC CARCINOMA
Where curative surgery is planned (61583/61586). |
| <input type="checkbox"/> Primary staging of proven NON-SMALL CELL LUNG CANCER
Where curative surgery or radiotherapy is planned (61529/61532). | <input type="checkbox"/> Primary staging of CARCINOMA OF THE HEAD & NECK. (61598) |
| <input type="checkbox"/> Suspected PRIMARY BRAIN TUMOUR
To guide surgical biopsy of the lesion and to assist in treatment planning (61535). | <input type="checkbox"/> Suspected residual or recurrent HEAD & NECK CANCER. (61604) |
| <input type="checkbox"/> RESIDUAL structural brain lesion based on anatomical imaging findings, after definitive therapy for GLIOMA. (61538) | <input type="checkbox"/> METASTATIC SCC involving cervical nodes
From an unknown primary site (61610/61613). |
| <input type="checkbox"/> REFRACTORY EPILEPSY which is being evaluated for surgery
Where results of standard assessment are inconclusive for localisation of the epileptogenic focus (61559). | <input type="checkbox"/> Staging of newly diagnosed or previously untreated LYMPHOMA. (61616/61619) |
| <input type="checkbox"/> Suspected RECURRENT COLORECTAL CARCINOMA
In a symptomatic patient for the evaluation of a residual structural lesion, after definitive therapy (61541/61544). | <input type="checkbox"/> Residual mass after treatment of LYMPHOMA. (61622/61625) |
| <input type="checkbox"/> Apparently isolated liver or pulmonary metastases following previous therapy for COLORECTAL CARCINOMA
Where surgical resection is planned (61547/61550). | <input type="checkbox"/> Suspected recurrent or residual LYMPHOMA. (61628/61631) |
| <input type="checkbox"/> Apparently limited metastatic disease from MALIGNANT MELANOMA
Where surgical resection is planned (61553/61556). | <input type="checkbox"/> Suspected bone or soft tissue SARCOMA
To guide biopsy where structural imaging suggests lesional heterogeneity (61634/61637). |
| <input type="checkbox"/> Suspected RECURRENT EPITHELIAL OVARIAN CARCINOMA
Based on equivocal anatomical imaging findings or an elevation of CA-125 (61565/61568). | <input type="checkbox"/> Staging of biopsy-proven bone or soft tissue SARCOMA
Being considered for resection of the primary or limited metastatic disease (61640/61643). |
| <input type="checkbox"/> Primary staging of proven UTERINE CERVICAL CARCINOMA
Prior to planned radical radiation therapy or combined modality therapy (61571/61574). | <input type="checkbox"/> Suspected residual or recurrent SARCOMA
On structural imaging after definitive therapy (61646/61649). |
| <input type="checkbox"/> Staging of proven OESOPHAGEAL CARCINOMA
Where curative surgery or chemoradiation is planned (61577/61580). | <input type="checkbox"/> MYOCARDIAL VIABILITY
Where revascularisation surgery is being considered and standard myocardial viability tests are negative or equivocal for ischaemia (61562). |
| | <input type="checkbox"/> UNFUNDED (specify) _____
<input type="checkbox"/> The patient is aware there will be a charge and is agreeable to this
<input type="checkbox"/> The referring institution is funding the study
Cost Code _____ Approved by _____
<input type="checkbox"/> Please consider performing this study on compassionate grounds |

Referring Consultant / Specialist*: _____ Provider #: _____
Phone: _____ Fax: _____ Signature: _____
Address: _____

***All sections must be completed and the patient must be Specialist referred. Incomplete referrals will not be booked.**

Referral ID Number (Office Use Only): _____